Shizuo Akira
Overview
Explore the profile of Shizuo Akira including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
997
Citations
122891
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hashimoto K, Abe Y, Fukushima K, Matsumoto Y, Saito H, Akamine Y, et al.
Emerg Infect Dis
. 2025 Mar;
31(3):624-627.
PMID: 40023820
We identified 2 novel species, Mycobacterium novusgordonae and M. shingordonae, from sputum specimens of pulmonary disease patients in Japan. Genetic and biochemical analyses revealed a close relationship with M. paragordonae....
2.
Hiramatsu Y, Suzuki K, Nishida T, Onoda N, Satoh T, Akira S, et al.
mBio
. 2025 Feb;
16(3):e0392124.
PMID: 39907486
No abstract available.
3.
Sakaguchi T, Nagahama Y, Hamada N, Singh S, Mikami H, Maeda K, et al.
Nutrients
. 2024 Dec;
16(23).
PMID: 39683544
Metabolic-dysfunction-associated steatotic liver disease (MASLD) is a progressive liver disorder that possesses metabolic dysfunction and shows steatohepatitis. Although the number of patients is globally increasing and many clinical studies have...
4.
Hobro A, Sakaguchi T, Akira S, Smith N
Chem Biomed Imaging
. 2024 Oct;
2(8):577-583.
PMID: 39473991
Raman imaging has the capability to provide unlabeled, spatially aware analysis of chemical components, with no assumptions. Several lifestyle diseases such as nonalcoholic steatohepatitis (NASH) can appear in the liver...
5.
Fukushima K, Matsumoto Y, Abe Y, Hashimoto K, Motooka D, Kitada S, et al.
Antimicrob Agents Chemother
. 2024 Oct;
68(11):e0121324.
PMID: 39377582
This single-center retrospective study aimed to analyze the variability of macrolide resistance (MR) in 68 patients with complex pulmonary disease. Among 25 patients treated without macrolides, 13 (52%) reverted to...
6.
Tanaka Y, Kumanogoh A, Atsumi T, Ishii T, Tago F, Aoki M, et al.
RMD Open
. 2024 Sep;
10(3).
PMID: 39289029
Objectives: To evaluate the safety, tolerability, pharmacokinetics (PK), biomarker response and efficacy of E6742 in a phase I/II study in patients with systemic lupus erythematosus (SLE). Methods: Two sequential cohorts...
7.
Nayer B, Tan J, Alshoubaki Y, Lu Y, Legrand J, Lau S, et al.
Nat Commun
. 2024 Sep;
15(1):7863.
PMID: 39251592
Regulatory T cells (Tregs) are crucial immune cells for tissue repair and regeneration. However, their potential as a cell-based regenerative therapy is not yet fully understood. Here, we show that...
8.
Sun X, Nagahama Y, Singh S, Kozakai Y, Nabeshima H, Fukushima K, et al.
Immunity
. 2024 May;
57(6):1360-1377.e13.
PMID: 38821052
Limited infiltration and activity of natural killer (NK) and T cells within the tumor microenvironment (TME) correlate with poor immunotherapy responses. Here, we examined the role of the endonuclease Regnase-1...
9.
Htun T, Tanaka H, Singh S, Diez D, Akira S
Int Immunol
. 2024 May;
36(10):497-516.
PMID: 38700370
Regnase-1 is an RNase that plays a critical role in negatively regulating immune responses by destabilizing inflammatory messenger RNAs (mRNAs). Dysfunction of Regnase-1 can be a major cause of various...
10.
Hosomi Y, Okamura T, Sakai K, Yuge H, Yoshimura T, Majima S, et al.
Nutrients
. 2024 Apr;
16(8).
PMID: 38674885
The cellular and molecular mechanisms of atherosclerosis are still unclear. Type 2 innate lymphocytes (ILC2) exhibit anti-inflammatory properties and protect against atherosclerosis. This study aimed to elucidate the pathogenesis of...